These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
228 related articles for article (PubMed ID: 34427990)
1. Improved survival with enasidenib versus standard of care in relapsed/refractory acute myeloid leukemia associated with IDH2 mutations using historical data and propensity score matching analysis. de Botton S; Brandwein JM; Wei AH; Pigneux A; Quesnel B; Thomas X; Legrand O; Recher C; Chantepie S; Hunault-Berger M; Boissel N; Nehme SA; Frattini MG; Tosolini A; Marion-Gallois R; Wang JJ; Cameron C; Siddiqui M; Hutton B; Milkovich G; Stein EM Cancer Med; 2021 Sep; 10(18):6336-6343. PubMed ID: 34427990 [TBL] [Abstract][Full Text] [Related]
14. Outcome of AML patients with IDH2 mutations in real world before the era of IDH2 inhibitors. Largeaud L; Bérard E; Bertoli S; Dufrechou S; Prade N; Gadaud N; Tavitian S; Bories P; Luquet I; Sarry A; De Mas V; Huguet F; Delabesse E; Récher C Leuk Res; 2019 Jun; 81():82-87. PubMed ID: 31055247 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy. Venugopal S; Takahashi K; Daver N; Maiti A; Borthakur G; Loghavi S; Short NJ; Ohanian M; Masarova L; Issa G; Wang X; Carlos BR; Yilmaz M; Kadia T; Andreeff M; Ravandi F; Konopleva M; Kantarjian HM; DiNardo CD Blood Cancer J; 2022 Jan; 12(1):10. PubMed ID: 35078972 [TBL] [Abstract][Full Text] [Related]
16. Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib. Quek L; David MD; Kennedy A; Metzner M; Amatangelo M; Shih A; Stoilova B; Quivoron C; Heiblig M; Willekens C; Saada V; Alsafadi S; Vijayabaskar MS; Peniket A; Bernard OA; Agresta S; Yen K; MacBeth K; Stein E; Vassiliou GS; Levine R; De Botton S; Thakurta A; Penard-Lacronique V; Vyas P Nat Med; 2018 Aug; 24(8):1167-1177. PubMed ID: 30013198 [TBL] [Abstract][Full Text] [Related]
17. Enasidenib for the treatment of acute myeloid leukemia. Dugan J; Pollyea D Expert Rev Clin Pharmacol; 2018 Aug; 11(8):755-760. PubMed ID: 29770715 [TBL] [Abstract][Full Text] [Related]
18. Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia. Pollyea DA; Tallman MS; de Botton S; Kantarjian HM; Collins R; Stein AS; Frattini MG; Xu Q; Tosolini A; See WL; MacBeth KJ; Agresta SV; Attar EC; DiNardo CD; Stein EM Leukemia; 2019 Nov; 33(11):2575-2584. PubMed ID: 30967620 [TBL] [Abstract][Full Text] [Related]
19. All-Trans Retinoic Acid Synergizes with Enasidenib to Induce Differentiation of IDH2-Mutant Acute Myeloid Leukemia Cells. Kim Y; Jeung HK; Cheong JW; Song J; Bae SH; Lee JI; Min YH Yonsei Med J; 2020 Sep; 61(9):762-773. PubMed ID: 32882760 [TBL] [Abstract][Full Text] [Related]